An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (XARELTO) Initiated in Secondary Care for the Prevention of Atherothrombotic Events in Patients Who Have Had Acute Coronary Syndrome in England and Wales

Trial Profile

An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (XARELTO) Initiated in Secondary Care for the Prevention of Atherothrombotic Events in Patients Who Have Had Acute Coronary Syndrome in England and Wales

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Atherosclerosis
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 28 Jan 2016 Accrual to date is 8% according to United Kingdom Clinical Research Network record.
    • 28 Jan 2016 Planned End Date changed from 1 Sep 2018 to 1 Jun 2019 according to United Kingdom Clinical Research Network record.
    • 10 Nov 2015 Accrual to date is 2% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top